The wAIHA Treatment Market Size was valued at ~USD 600 million in 2025 and is projected to reach ~USD 2.4 billion by 2036, growing at a CAGR of 14.4% | DelveInsight

DelveInsight's "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the Warm Autoimmune Hemolytic Anemia, historical and forecasted epidemiology and the Warm Autoimmune Hemolytic Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore Warm Autoimmune Hemolytic Anemia market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report
• In 2025, the total number of diagnosed prevalent cases of AIHA across the 7MM was estimated at approximately 120,000.
• In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.
• In 2025, females accounted for about 60% of diagnosed prevalent wAIHA cases across EU4 and the UK, while males represented around 40%.
• In 2025, across EU4 and the UK, the ≥65 age group accounted for around 55% of wAIHA cases, followed by the 45-64 age group at approximately 25%.
• In 2025, in Japan, severe wAIHA accounted for around 420 cases, while non-severe cases were estimated at approximately 600.
• The leading Warm Autoimmune Hemolytic AnemiaCompanies such as Johnson & Johnson, Rigel Pharmaceuticals, Sanofi, Apellis Pharmaceuticals, Immunovant, Incyte Corporation, Zenas BioPharma, Bristol Myers Squibb, and others.
• Promising Warm Autoimmune Hemolytic Anemia Therapies such as INCA000585, Povetacicept, Ianalumab, APL-2, Fostamatinib Disodium, ANX005, Fostamatinib 150 mg bid, Rilzabrutinib, HMPL-523(300mg PO QD) and others.

Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Epidemiology Insights in the 7MM
Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology is a rare autoimmune blood disorder with a low global incidence, typically affecting a small but clinically significant patient population. It accounts for the majority of autoimmune hemolytic anemia cases and is more frequently observed in adults, particularly females. The epidemiology of wAIHA is influenced by factors such as increasing prevalence of autoimmune diseases, improved diagnostic awareness, and better detection of secondary cases associated with conditions like lupus, lymphoproliferative disorders, and infections. The diagnosed patient pool is gradually expanding across major healthcare markets due to advancements in laboratory testing and growing clinical recognition, with developed regions such as North America contributing a significant share of total cases.

Download the report to understand which factors are driving Warm Autoimmune Hemolytic Anemia epidemiology trends @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Marketed Drugs
• IMAAVY (nipocalimab): Johnson & Johnson
Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor (FcRn), inhibiting IgG recycling and reducing circulating pathogenic IgG antibodies. By lowering autoantibody levels, it has potential therapeutic benefits in IgG-mediated conditions such as warm autoimmune hemolytic anemia (wAIHA), where autoantibodies drive red blood cell destruction. Nipocalimab is currently being evaluated in a Phase II/III clinical trial for the treatment of warm wAIHA. In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY as a treatment for patients with wAIHA.

Warm Autoimmune Hemolytic Anemia Competitive Landscape
The competitive landscape of Warm Autoimmune Hemolytic Anemia (wAIHA) is rapidly evolving, driven by a high unmet medical need and the absence of any widely approved disease-specific therapies. The market is currently transitioning from conventional off-label immunosuppressive treatments toward targeted biologics and mechanism-based therapies that aim to improve long-term disease control and safety outcomes.

Discover the future of Warm Autoimmune Hemolytic Anemia Treatments with DelveInsight's latest market report @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Warm Autoimmune Hemolytic Anemia Companies
Johnson & Johnson, Rigel Pharmaceuticals, Sanofi, Apellis Pharmaceuticals, Immunovant, Incyte Corporation, Zenas BioPharma, Bristol Myers Squibb, and others.

Warm Autoimmune Hemolytic Anemia Market Outlook
The wAIHA market is entering a phase of transformation after decades of relying on broad immunosuppression with corticosteroids, rituximab, and other nonspecific immunosuppressants. These treatments often provide temporary disease control but are associated with frequent relapse, steroid dependence, and cumulative toxicity. Despite the significant disease burden, there are currently no therapies specifically approved for wAIHA in most major markets, highlighting a substantial unmet medical need.

From market size to emerging drugs, find it all in our latest report. Read now! @ Warm Autoimmune Hemolytic Anemia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Warm Autoimmune Hemolytic Anemia Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Warm Autoimmune Hemolytic Anemia Companies- Johnson & Johnson, Rigel Pharmaceuticals, Sanofi, Apellis Pharmaceuticals, Immunovant, Incyte Corporation, Zenas BioPharma, Bristol Myers Squibb, and others.
• Warm Autoimmune Hemolytic Anemia Therapies- INCA000585, Povetacicept, Ianalumab, APL-2, Fostamatinib Disodium, ANX005, Fostamatinib 150 mg bid, Rilzabrutinib, HMPL-523(300mg PO QD) and others.
• Warm Autoimmune Hemolytic Anemia Therapeutic Assessment: Warm Autoimmune Hemolytic Anemia Current marketed and Warm Autoimmune Hemolytic Anemia Emerging Therapies
• Warm Autoimmune Hemolytic Anemia Market Dynamics: Warm Autoimmune Hemolytic Anemia market drivers and Warm Autoimmune Hemolytic Anemia market barriers
• wAIHA Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Warm Autoimmune Hemolytic Anemia Unmet Needs, KOL's views, Analyst's views, Warm Autoimmune Hemolytic Anemia Market Access and Reimbursement

Table of Contents
1. Key Insights
2. wAIHA Market Report Introduction
3. wAIHA Market Overview at a Glance
4. wAIHA Epidemiology and Market Forecast Methodology
5. wAIHA Executive Summary
6. Key Events
7. wAIHA Disease Background and Overview
8. wAIHA Treatment and Management
9. wAIHA Epidemiology and Patient Population
10. wAIHA Patient Journey
11. wAIHA Marketed Therapies
12. wAIHA Emerging Therapies
13. wAIHA: 7 Major Market Analysis
14. wAIHA KOL Views
15. wAIHA SWOT Analysis
16. wAIHA Unmet Needs
17. wAIHA Reimbursement Scenario
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.